DANIEL J BOOSER to Antineoplastic Agents, Phytogenic
This is a "connection" page, showing publications DANIEL J BOOSER has written about Antineoplastic Agents, Phytogenic.
Connection Strength
0.478
-
Canalicular stenosis secondary to docetaxel (taxotere): a newly recognized side effect. Ophthalmology. 2001 May; 108(5):994-5.
Score: 0.136
-
A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer. Clin Cancer Res. 2002 Nov; 8(11):3360-8.
Score: 0.038
-
Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer. Ophthalmology. 2002 Jun; 109(6):1188-91.
Score: 0.037
-
Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res. 2002 May; 8(5):1073-9.
Score: 0.037
-
Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect. Ann Oncol. 2002 Feb; 13(2):218-21.
Score: 0.036
-
Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: cumulative toxicities limit dose escalation. Cancer Invest. 2001; 19(5):459-66.
Score: 0.033
-
Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy. Cancer. 2000 Dec 01; 89(11):2195-201.
Score: 0.033
-
Phase I study of vinorelbine by 96-hour infusion in advanced metastatic breast cancer. Am J Clin Oncol. 2000 Apr; 23(2):117-21.
Score: 0.032
-
Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol. 1999 Nov; 17(11):3412-7.
Score: 0.031
-
A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol. 1998 Oct; 16(10):3362-8.
Score: 0.028
-
A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic breast cancer. Clin Cancer Res. 2003 Jul; 9(7):2426-34.
Score: 0.010
-
A phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma: final analysis with 10-year follow-up. Cancer. 2003 Jun 01; 97(11):2716-23.
Score: 0.010
-
Phase I study of eniluracil and oral 5-fluorouracil in combination with docetaxel in the treatment of patients with metastatic breast carcinoma. Cancer. 2002 May 01; 94(9):2321-6.
Score: 0.009
-
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2002 Apr 01; 20(7):1800-8.
Score: 0.009